Mechanisms by which thiazolidinediones enhance insulin action

Trends in Endocrinology and Metabolism

Volumn 10, Issue 1, 1999, Pages 9-13

  Reginato, Mauricio J ^a   Lazar, Mitchell A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; TROGLITAZONE;

ADIPOSE TISSUE; DRUG STRUCTURE; HORMONE ACTION; HUMAN; INSULIN METABOLISM; LIGAND BINDING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKELETAL MUSCLE; TRANSACTIVATION;

EID: 0033039662     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(98)00110-6     Document Type: Review

References (72)

1. Olefsky J.M., Ciaraldi T.P., Kolterman O.G. Mechanisms of insulin resistance in non-insulin-dependent (type III) diabetes. Am. J. Med. 79:1985;12-22.
2. Larkins R.G. New concepts for treatment of non-insulin-dependent diabetes mellitus. Trends Endocrinol. Metab. 8:1997;187-191.
3. Henry R.R. Thiazolidinediones. Endocrinol. Metab. Clin. North Am. 26:1997;553-573.
4. Fujita T.et al. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2, 4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes. 32:1983;804-810.
5. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 37:1988;1549-1558.
6. Suter S.L., Nolan J.J., Wallace P., Gumbiner B., Olefsky J.M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:1992;193-203.
7. Kumar S.et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone study group [published erratum appears in Diabetologia (1996) 39, 12451]. Diabetologia. 39:1996;701-709.
8. Ehrmann D.A.et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and ribrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82:1997;2108-2116.
9. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81:1996;3299-3306.
10. Schwartz S., Raskin P., Fonseca V., Graveline J.F. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and exogenous insulin study group. New Engl. J. Med. 338:1998;861-866.
11. Spencer C.M., Markham A. Troglitazone. Drugs. 54:1997;89-101.
12. Inzucchi S.E.et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. New Engl. J. Med. 338:1998;867-872.
13. Watkins P.B., Whitcomb R.W. Hepatic dysfunction associated with troglitazone. New Engl. J. Med. 338:1998;916-917.
14. Neuschwander-Tetri B.A.et al. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann. Intern. Med. 129:1998;38-41.
15. Gitlin N., Julie N.L., Spurr C.L., Lim K.N., Juarbe H.M. Two cases of severe clinical and histological hepatotoxicity associated with troglitazone. Ann. Intern. Med. 129:1998;36-38.
16. Imura H. A novel antidiabetic drug, troglitazone - reason for hope and concern. New Engl. J. Med. 338:1997;908-909.
17. Kawamatsu Y., Saraie T., Imamiya E., Nishikawa K., Hamuro Y. Studies on antihyperlipidemic agents. I. Synthesis and hypolipidemic activities of phenoxyphenyl alkanoic acid derivatives. Arzneimittelforschung. 30:1980;454-459.
18. Hiragun A., Sato M., Mitsui H. Preadipocyte differentiation in vitro: identification of a highly active adipogenic agent. J. Cell. Physiol. 134:1988;124-130.
19. Kletzien R.F., Clarke S.D., Ulrich R.G. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol. 41:1992;393-398.
20. Chawla A., Lazar M.A. Peroxisome proliferator and retinoid signalling pathways coregulate pre- adipocyte phenotype and survival. Proc. Natl. Acad. Sci. U. S. A. 91:1994;1786-1790.
21. Chawla A., Schwarz E.J., Dimaculangan D.D., Lazar M.A. Peroxisome proliferator-activated receptor γ (PPARγ): adipose predominant expression and induction early in adipocyte differentiation. Endocrinology. 135:1994;798-800.
22. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPARγ 2, a lipid- activated transcription factor. Cell. 79:1994;1147-1156.
23. Lehmann J.M.et al. An antidiabetic thiazolidinedione is a high affinity ligand for the nuclear peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270:1995;12953-12956.
24. Mangelsdorf D.J.et al. The nuclear receptor superfamily: the second decade. Cell. 83:1995;835-839.
25. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell. 83:1995;841-850.
26. Glass C.K., Rose D.W., Rosenfeld M.G. Nuclear receptor coactivators. Curr. Opin. Cell. Biol. 9:1997;222-232.
27. Lemberger T., Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu. Rev. Cell Dev. Biol. 12:1996;335-363.
28. Martin G., Schoonjans K., Lefebvre A.M., Staels B., Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators. J. Biol. Chem. 272:1997;28210-28217.
29. Hu E., Tontonoz P., Spiegelman B.M. Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPα Proc. Natl. Acad. Sci. U. S. A. 92:1995;9856-9860.
30. Forman B.M.et al. 15-deoxy, delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ Cell. 83:1995;803-812.
31. Kliewer S.A.et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 83:1995;813-819.
32. Yu K.et al. Differential activation of peroxisome proliferator- activated receptors by eicosanoids. J. Biol. Chem. 270:1995;23975-23983.
33. Willson T.M.et al. The structure-activity relationship between peroxisome proliferator-activated receptor γ and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39:1996;665-668.
34. Berger J.et al. Thiazolidinediones produce a conformational change in peroxisome proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 137:1996;4189-4195.
35. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., Evans R.M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 358:1992;771-774.
36. Schulman I.G., Shao G., Heyman R.A. Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor γ (PPARγ) heterodimers: intermolecular synergy requires only the PPARγ hormone-dependent activation function. Mol. Cell. Biol. 18:1998;3483-3494.
37. Mukherjee R.et al. Sensitization of diabetes and obese mice to insulin by retinoid X receptor agonists. Nature. 386:1997;407-410.
38. Vidal-Puig A.J.et al. Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99:1997;2416-2422.
39. DuBois R.N.et al. The nuclear eicosanoid receptor PPARγ is aberrantly expressed in colonic cancers. Carcinogenesis. 19:1998;49-53.
40. Fajas L.et al. The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem. 272:1997;18779-18789.
41. Mueller E.et al. Terminal differentiation of human breast cancer through PPARγ Mol. Cell. 1:1998;465-470.
42. Michael L.F., Lazar M.A., Mendelson C.R. PPARγ 1 expression is induced during cyclic AMP-stimulated differentiation of alveolar type II pneumocytes. Endocrinology. 138:1997;3695-3703.
43. Greene M.E.et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 4:1995;281-299.
44. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391:1998;79-82.
45. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:1998;241-252.
46. Parks K.S.et al. PPAR-γ gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes. 46:1997;1230-1234.
47. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPARγ 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1994;1224-1234.
48. Okuno A.et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101:1998;1354-1361.
49. Wu Z., Xie Y., Morrison R.F., Bucher N.L., Farmer S.R. PPARγ induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPα during the conversion of 3T3 fibroblasts into adipocytes. J. Clin. Invest. 101:1998;22-32.
50. Young P.W.et al. Repeat treatment of obese mice with BRL49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes. 44:1995;1087-1092.
51. Marin P.et al. Uptake of glucose carbon in muscle glycogen and adipose tissue triglycerides in vivo in humans. Am. J. Physiol. 263:1992;E473.
52. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 259:1993;87-91.
53. Uysal K.T., Wiesbrock S.M., Marion M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature. 389:1997;610-614.
54. Hofmann C.et al. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology. 134:1994;264-270.
55. Szalkowski D., White-Carrington S., Berger J., Zhang B. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology. 136:1995;1474-1481.
56. Peraldi P., Xu M., Spiegelman B.M. Thiazolidinediones block tumor necrosis factor-α -induced inhibition of insulin signaling. J. Clin. Invest. 100:1997;863-1869.
57. Murase K., Odaka H., Suzuki M., Tayuki N., Ikeda H. Pioglitazone time-dependently reduces tumour necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia. 41:1998;257-264.
58. Zhang Y.et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 372:1994;425-432.
59. Considine R.V.et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Engl. J. Med. 334:1996;292-295.
60. Zimmet P.Z.et al. Is there a relationship between leptin and insulin sensitivity independent of obesity? A population-based study in the Indian Ocean nation of Mauritius. Int. J. Obes. Relat. Metab. Disord. 22:1998;171-177.
61. Kallen C.B., Lazar M.A. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-Ll adipocytes. Proc. Natl. Acad. Sci. U. S. A. 93;1996:5793-5796.
62. DeVos P.et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J. Clin. Invest. 98:1996;1004-1009.
63. Zhang B.et al. Down-regulation of the expression of the Obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J. Biol. Chem. 271:1996;9455-9459.
64. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 46:1997;1-10.
65. Groop L.C.et al. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin. Endocrinol. Metab. 72:1991;96-107.
66. Schoojans K., Martin G., Staels B., Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8:1997;159-166.
67. Burant C.F.et al. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100:1997;2900-2908.
68. Park K.S.et al. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects. J. Clin. Endocrinol. Metab. 83:1998;1636-1643.
69. Adams M., Reginato M.J., Shao D., Lazar M.A., Chatterjee V.K. Transcriptional activation by PPARγ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem. 272:1997;5128-5132.
70. Reginato M.J., Krakow S.L., Bailey S.T., Lazar M.A. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor γ J. Biol. Chem. 273:1998;1855-1858.
71. Hu E., Kim J.B., Sarraf P., Spiegelman B.M. Inhibition of adipogenesis through MAP kinase- mediated phosphorylation of PPARγ Science. 274:1996;2100-2103.
72. Camp H.S., Tafuri S.R. Regulation of peroxisome proliferator-activated receptor γ activity by mitogeb-activated protein kinase. J. Biol. Chem. 272:1997;13452-13457.